Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics. (2019)
Attributed to:
Gene therapy for refractory epilepsy
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1126/sciadv.aaw1567
PubMed Identifier: 31001591
Publication URI: http://europepmc.org/abstract/MED/31001591
Type: Journal Article/Review
Volume: 5
Parent Publication: Science advances
Issue: 4
ISSN: 2375-2548